Free Cash Flow

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

The AI defense firm's stock surged after announcing a share repurchase, a move reflecting deep internal confidence amid a booming defense-tech market.

With a key drill target identified at its Rio Tinto-partnered project in Montana, the junior explorer is poised for a pivotal year in the hunt for copper.

Pharma giant GSK partners with biotech CAMP4, leveraging novel RNA-boosting tech to develop new therapies for neurodegenerative and kidney diseases.

After a challenging year marked by a mine fire and merger pains, Core Natural Resources is back online, signaling a major financial turnaround for 2026.

Molecular Partners readies for a pivotal presentation at the J.P. Morgan conference, showcasing its next-gen DARPin therapeutics for hard-to-treat cancers.

Vision Marine secures critical funds for its electric boat ambitions, but the deal's terms raise questions about shareholder value and its financial health.

Ninepoint Partners doubles its energy fund's target yield to a massive 14%. We dig into the sustainability, risks, and the new reality of energy profits.

An international expert panel endorses an advanced wound therapy, potentially revolutionizing patient recovery and boosting a key player in the med-tech market.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

YXT.com's $100M shelf registration gives it a war chest for AI growth, but investors weigh the promise of innovation against current financial pressures.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

Swedish crypto firm Virtune extends its deal with table tennis champ Truls Möregårdh, a move signaling a strategy to win mainstream trust in a regulated Europe.

A new study reveals Gen X faces a shocking $400K retirement shortfall, caught between fading pensions and an imperfect 401(k) system. Are they prepared?

A new partnership brings carbon footprint data directly into developer pull requests, empowering engineers to build greener cloud infrastructure from the start.

Can-Fite BioPharma eyes key 2026 data readouts for its late-stage oral drugs targeting advanced liver cancer, psoriasis, and other unmet medical needs.

Recognized by Chambers USA, ASK LLP is proving that specialized expertise can deliver massive settlements for victims in landmark national cases.

Riding a wave of record sales from its iDose TR implant, Glaukos is set to update investors on its explosive growth and the launch of its new drug, Epioxa.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.